Gold prices edge higher on raised Fed rate cut hopes
Investing.com - Deutsche Bank (ETR:DBKGn) lowered its price target on Merck KGaA (ETR:MRK) (OTC:MKGAF) to EUR133.00 from EUR140.00 while maintaining a Buy rating following the company’s mixed second-quarter results.
The research firm cited the need for a quarter that triggers positive consensus earnings revisions to help the stock regain momentum after recent downward adjustments to estimates.
Deutsche Bank expressed optimism that Merck’s 2025 guidance has been reduced enough to potentially achieve stabilization with upcoming third-quarter results.
Despite growing investor frustration with Merck’s group structure, Deutsche Bank believes there remains underlying value to be unlocked with the current corporate setup.
The new price target of EUR133 represents more than 20% upside potential from current levels, with Deutsche Bank remaining positive on the investment case due to attractive valuation and improving performance in Merck’s Life Science business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.